Putnam Investments’s KalVista Pharmaceuticals KALV Stock Holding History

Putnam Investments’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-42,857	Closed	-$398K	–	1304
2016 Q2	$398K	Hold	42,857	–	–	﹤0.01%	1229
2016 Q1	$386K	Hold	42,857	–	–	﹤0.01%	1289
2015 Q4	$2.17M	Sell	42,857 -2,534	-6%	-$133K	﹤0.01%	953
2015 Q3	$2.27M	Buy	45,391 +50	+0.1%	+$4.26K	0.01%	955
2015 Q2	$4.54M	Buy	+45,341	New	+$4.5M	0.01%	766

Other funds holding KALV

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

AFG

Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Putnam Investments's KALV Position: Q3 2016 in Review

Putnam Investments sold out of KalVista Pharmaceuticals (KALV) in Q3 2016, closing a stake of 42,857 shares — an estimated $398K sold.

Putnam Investments first reported a position in KALV in Q2 2015 and held it in 5 quarters. The position peaked at $4.54M in Q2 2015. 21 funds tracked by Wall St. Rank hold KALV as of Q3 2016.

Putnam Investments reported no remaining KalVista Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Putnam Investments sold 42,857 KalVista Pharmaceuticals shares in Q3 2016, an estimated $398K.
Putnam Investments first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 5 quarters.
Putnam Investments's KalVista Pharmaceuticals position peaked at $4.54M in Q2 2015.
21 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2016.

Based on Putnam Investments's 13F filing for Q3 2016, filed 14 Nov 2016.